Study of Midomafetamine in Healthy Adults
Part of paid clinical trials in Overland Park, Kansas.
- Sponsor
- Resilient Pharmaceuticals
- Study ID
- NCT07584720
- Phase
- PHASE1
- Status
- Active Not Recruiting
Conditions
- Healthy Volunteers
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- Midomafetamine HCl — DRUGMidomafetamine HCl is administered orally to study participants.
Study Details
This Phase 1 study is designed to evaluate the safety and tolerability of midomafetamine in healthy adult participants. The study will also assess how the drug is processed in the body and characterize its effects following administration at two dose levels, including evaluation of cardiac safety using electrocardiographic assessments. This is a single-center, open-label study in which participants will be enrolled into one of two cohorts receiving either a therapeutic dose or a supratherapeutic dose of midomafetamine. Participants will receive study drug in a split dose administration (an initial dose followed by an additional dose 1.5 hours later) and will undergo clinical assessments, laboratory testing, electrocardiographic monitoring, and monitoring for adverse events. Information collected from this study will be used to support the ongoing clinical development of midomafetamine.
Key Dates
- First listed
- May 13, 2026
- Start date
- Apr 23, 2026
- Status verified
- Jun 2026
- Primary completion
- Jul 23, 2026
- Completion
- Feb 28, 2027
Study Design
- Enrollment
- 32 participants (estimated)
- Allocation
- NA
- Intervention model
- SEQUENTIAL
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: ExperimentalParticipants receive midomafetamine administered in sequential dose cohorts. One cohort receives a targeted therapeutic dose administered in a split manner, and a subsequent cohort receives a supratherapeutic dose administered in a split manner.
Primary Outcome Measure
Incidence of Adverse Events [ Time Frame: From signing of informed consent through End of Study visit (Day 30 +/- 2 Days) ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Dr. Vince Clinical Research | Overland Park | Kansas | 66212 | - |
Find similar trials in Overland Park, KS
Related Studies
- A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseasePHASE1/PHASE2 · Recruiting · Bristol-Myers Squibb · Birmingham, Alabama
- A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult ParticipantsPHASE1 · Recruiting · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Anaheim, California
- Evaluation of Patients With Mood and Anxiety Disorders and Healthy VolunteersRecruiting · National Institute of Mental Health (NIMH) · Bethesda, Maryland
- Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family MembersEnrolling By Invitation · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland